Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B, Duh MS, Bhak RH, DerSarkissian M, Huynh L, Wang K, Wojciehowski J, Wu M, Wornson B, Niyazov A, Demetri GD. Arondekar B, et al. Among authors: niyazov a. Clin Cancer Res. 2022 Jan 1;28(1):27-35. doi: 10.1158/1078-0432.CCR-21-2639. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667027 Free PMC article.
Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D, Biskupiak J, Oderda G, Burgoyne D, Malone DC, Arondekar B, Niyazov A. Brixner D, et al. Among authors: niyazov a. J Manag Care Spec Pharm. 2021 Aug;27(8):1096-1105. doi: 10.18553/jmcp.2021.27.8.1096. J Manag Care Spec Pharm. 2021. PMID: 34337998 Free PMC article.
Differences in responses for categorical data were compared using a Pearson Chi-Square or a Fisher's Exact test. Two-tailed values are reported and a level of 0.05 was used to indicate statistical significance. ...Burgoyne was a consultant for Pfizer o …
Differences in responses for categorical data were compared using a Pearson Chi-Square or a Fisher's Exact test. Two-tailed va …
Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J, Oderda G, Brixner D, Burgoyne D, Arondekar B, Niyazov A. Biskupiak J, et al. Among authors: niyazov a. J Manag Care Spec Pharm. 2021 Nov;27(11):1560-1567. doi: 10.18553/jmcp.2021.27.11.1560. J Manag Care Spec Pharm. 2021. PMID: 34714111 Free PMC article.
When comparing therapies with similar safety/efficacy profiles, 68.6% of payers reported economic models as helpful a moderate amount, a lot, or a great deal. Over one-third of payers (37.3%) were willing to partner with manufacturers on economic models using …
When comparing therapies with similar safety/efficacy profiles, 68.6% of payers reported economic models as helpful a moderate amount …
Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G, Brixner D, Biskupiak J, Burgoyne D, Arondekar B, Deal LS, Quek RG, Niyazov A. Oderda G, et al. Among authors: niyazov a. J Manag Care Spec Pharm. 2022 Feb;28(2):188-195. doi: 10.18553/jmcp.2021.21223. Epub 2021 Nov 22. J Manag Care Spec Pharm. 2022. PMID: 34806908
Almost half (47.1%) suggested formulary review would be influenced by a lack of PRO evidence from oncology clinical trials either somewhat, much, or a great deal. ...Biskupiak, Oderda, and Brixner are managers of Millcreek Outcomes Group and were paid as consultants …
Almost half (47.1%) suggested formulary review would be influenced by a lack of PRO evidence from oncology clinical trials either som …
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP. Mahtani R, et al. Among authors: niyazov a. Adv Ther. 2023 Jan;40(1):331-348. doi: 10.1007/s12325-022-02302-2. Epub 2022 Oct 28. Adv Ther. 2023. PMID: 36333567 Free PMC article.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: niyazov a. Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. Breast. 2022. PMID: 36368161 Free PMC article.
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: niyazov a. BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. BMC Cancer. 2022. PMID: 36550413 Free PMC article.
31 results